Semaglutide 5/10 mg

Composition

Each pack contains:

• One vial with Semaglutide – 5–10 mg (GLP-1 receptor agonist)
• One ampoule with 2 ml sterile water for injection

Pharmacological Effects

• Glucose-dependent insulin secretion: Lowers blood glucose without significant hypoglycemia risk.
• Glucagon suppression: Reduces hepatic glucose output.
• Delayed gastric emptying: Promotes fullness and supports weight loss.
• Cardioprotective effects: Demonstrated reduction in major cardiovascular events (MACE) in T2D patients.

Indications

• Type 2 Diabetes (Ozempic® / Rybelsus®)
  • Ozempic (injection): 0.5–2 mg weekly.
  • Rybelsus (oral): 3–14 mg daily.
• Chronic Weight Management (Wegovy®)
  • 0.25 mg → 2.4 mg weekly (gradual escalation over 16–20 weeks).

Recommended Dose

Reconstitution

• If lyophilized: Add 1–2 mL bacteriostatic water (e.g., 5 mg in 1 mL → 5 mg/mL concentration).

Dosing (Off-label / Research)

• For Diabetes:
  • Start: 0.25 mg weekly × 4 weeks.
  • Then increase to 0.5 mg weekly.
  • Typical max: 1–2 mg weekly.
• For Weight Loss:
  • Slow escalation recommended:
  • 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg weekly over 4–5 months.
• A 5 mg vial is typically used for multiple weekly doses (drawing 0.25–1 mg per injection).

Side Effects

Common (10–30%)

• Nausea, vomiting, diarrhea, constipation.
• Abdominal discomfort or pain.

Less Common

• Gallbladder issues (e.g., cholelithiasis).
• Hypoglycemia (especially with insulin or sulfonylureas).
• Pancreatitis (rare; discontinue if severe abdominal pain occurs).

Black Box Warning (Rodent Studies)

• Thyroid C-cell tumors — contraindicated in patients with a history of medullary thyroid carcinoma (MTC) or MEN2.

Contraindication

• History of medullary thyroid carcinoma (MTC) or MEN2.
• Pregnancy (avoid unless benefits outweigh risks).
• Severe gastrointestinal disease (e.g., gastroparesis).
• Hypersensitivity to Semaglutide or other GLP-1 agonists.

Storage Conditions

• Unopened (unreconstituted): Refrigerate at 2–8°C (36–46°F). Do not freeze.
• After reconstitution: Refrigerate at 2–8°C and use within 30 days (when mixed with bacteriostatic water).
• Commercial pens (Ozempic/Wegovy): Follow manufacturer guidelines once opened.

Disclaimer: This product is not for human use. It is intended for laboratory research only. Not for diagnostic, therapeutic, or veterinary purposes. Buyer assumes all responsibility for proper handling and legal compliance. Keep out of reach of children. Not for consumption.